P233 Adalimumab produces high responder and remission rates and has an independent effect on quality of life in Crohn's disease patients

P232 Shorter infliximab administration infusion times in Crohn’s disease are safe and well tolerated S. Peake1 *, J. Landy1, C. Tee2, T. Tyrrell3, M. O’Connor4, H. Middleton5, D. Bernardo2, A. Hart4. 1St Mark’s Hospital, London, United Kingdom, 2Antigen Presentation Research Group, Imperial College, London, United Kingdom, 3St Mark’s Hospital, IBD, London, United Kingdom, 4St Mark’s Hospital, Gastroenterology, London, United Kingdom, 5St Marks Hospital, IBD Unit, London, United Kingdom